SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity - Summary - MDSpire

SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity

  • By

  • Barbara Pala

  • Mariagrazia Piscione

  • Maria Carmela Di Marcantonio

  • Francesco Cribari

  • Roberta Vitale

  • Thomas Baldi

  • Ada Popolo

  • Gabriella Mincione

  • June 9, 2026

  • 0 min

Share

Objective:

To evaluate the association between simvastatin therapy and cardiac outcomes in patients treated with doxorubicin-based chemotherapy.

Key Findings:
  • Seven patients developed heart failure with reduced ejection fraction (HFrEF).
  • Statin therapy was associated with a lower incidence of ECG abnormalities.
  • Statin-treated patients showed significantly smaller declines in LVEF compared to non-users.
  • Simvastatin exposure was independently associated with preservation of systolic function and attenuation of QT/QTc prolongation.
  • Propensity score-weighted analyses confirmed the robustness of the association between statin therapy and reduced risk of ECG abnormalities.
Interpretation:

Remove this section as it contains unsupported conclusions.

Limitations:
  • Retrospective design limits causal inference.
  • Sample size may not be large enough to generalize findings.
Conclusion:

Revise to state only the findings without implications or interpretations.

Original Source(s)

SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity

  • by Barbara Pala, Mariagrazia Piscione, Maria Carmela Di Marcantonio, Francesco Cribari, Roberta Vitale, Thomas Baldi, Ada Popolo, Gabriella Mincione

  • June 9, 2026

Related Content

Prevalence of asymptomatic atrial fibrillation and risk factors associated with asymptomatic status: a systematic review and meta-analysis

Thirty-Day Readmission Risk Among Adults Hospitalized for Heart Failure or Acute Myocardial Infarction With and Without HIV

Longitudinal trajectories of albuminuria and risk of subclinical and clinical heart failure, atrial fibrillation, and coronary heart disease: the MESA study